Latest news with #SanofiIndia
Time of India
3 days ago
- Business
- Time of India
Emcure, Sanofi tie up for anti-diabetic range
New Delhi: Emcure Pharma and Sanofi India announced that they entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India, effective immediately. Emcure will exclusively distribute and promote the range of products, which include brands like Amaryl and Cetapin.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Stock Market LIVE: Sensex falls 190 pts, Nifty below 25,200; Angel One up 2%, Tech Mahindra down 2%
Sensex Today | Stock Market LIVE on Thursday, July 17, 2025: In the broader markets, the Nifty MidCap index erased gains to trade 0.07 per cent lower, while the Nifty SmallCap index held onto its gain 10:51 AM Stock Market LIVE Updates: Emcure Pharma, Sanofi India shares edge higher; what's behind the move? Stock Market LIVE Updates: Shares of pharma major Emcure Pharmaceuticals rose over 2 per cent to hit an intraday high of ₹1,394.8 on the National Stock Exchange (NSE) after the company announced a distribution and promotion partnership with Sanofi India on Wednesday. At 9:30 AM, the stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5. In comparison, the benchmark NSE Nifty50 index was trading marginally down by 15.5 points at 25,196.55 levels. The total market capitalisation of Emcure Pharmaceuticals stood at ₹26,216.58 crore. READ MORE 10:21 AM Stock Market LIVE Updates: Will Tech Mahindra stock rise or fall post Q1 performance Stock Market LIVE Updates: Tech Mahindra stock slipped over 2 per cent in early trade to a low of ₹1,572 on Thursday a day after reporting the June (Q1) quarter results. The IT firm - Tech Mahindra reported a 33.9 per cent growth in consolidated net profit at ₹1,140.60 crore for Q1FY26 as against ₹851.50 crore reported a year ago. Revenue from operations rose by 2.7 per cent year-on-year (YoY) to ₹13,351.20 crore from ₹13,005.50 crore. However, on a sequential basis (quarter-on-quarter) net profit was down 2.2 per cent, and revenue dipped 0.2 per cent. READ MORE 9:30 AM Stock Market LIVE Updates: Sector check 9:22 AM Stock Market LIVE Updates: Sensex, Nifty flat after market opens Stock Market LIVE Updates: BSE Sensex was flat, below 82,650-mark after the market opened. Similary, NSE Nifty50 was below 25,250-level, down 7 points. 9:10 AM Stock Market LIVE Updates: Sensex up over 100 pts in pre-open Connect with us on WhatsApp
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Emcure Pharma, Sanofi India shares edge higher; what's behind the move?
Emcure Pharmaceuticals share price today: Shares of pharma major Emcure Pharmaceuticals rose over 2 per cent to hit an intraday high of ₹1,394.8 on the National Stock Exchange (NSE) after the company announced a distribution and promotion partnership with Sanofi India on Wednesday. At 9:30 AM, the stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5. In comparison, the benchmark NSE Nifty50 index was trading marginally down by 15.5 points at 25,196.55 levels. The total market capitalisation of Emcure Pharmaceuticals stood at ₹26,216.58 crore. Shares of Sanofi India also gained around 1.5 per cent to hit an intraday high of ₹5,975. At the time of writing, the stock was quoting 1.2 per cent higher at ₹5,956.5. Emcure Pharmaceuticals and Sanofi India have entered a distribution and promotion partnership aimed at expanding access to Sanofi's oral anti-diabetic (OAD) products across India. Effective immediately, Emcume will exclusively distribute and promote Sanofi's OAD range of products, including established brands like Amaryl and Cetapin. However, Sanofi India will continue to own and manufacture these brands across Sanofi's plants in India and internationally. "Emcure will leverage its strengths to engage healthcare professionals and expand the reach of these therapeutic solutions for patients who need them across all of India," the company said in an exchange filing. "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country,' said Satish Mehta, chief executive officer and managing director at Emcure Pharmaceuticals. About Emcure Pharma Headquartered in Pune, Emcure Pharmaceuticals is engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, Emcure is ranked as the 12th largest pharma company in India in terms of domestic sales for MAT June 2024. The company has a presence in more than 70 countries globally, including Europe and Canada.
Time of India
4 days ago
- Business
- Time of India
Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India
Emcure Pharmaceuticals Ltd and Sanofi India Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India with immediate effect. Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement. Explore courses from Top Institutes in Select a Course Category Operations Management Data Analytics Finance Data Science Artificial Intelligence MBA Product Management PGDM Technology Project Management Healthcare Cybersecurity Public Policy Degree MCA Leadership Management CXO Others Digital Marketing healthcare others Design Thinking Data Science Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details Sanofi India will continue to own and manufacture these brands across its plants in India and internationally, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hörspezialisten verlieren Kunden: Dieses 89€-Gerät spricht sich herum Top Trending News Today Mehr erfahren Undo "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them," Emcure Pharmaceuticals CEO and MD Satish Mehta said. Further, he said, "This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country." Live Events Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, "With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both - the patients who need them and the healthcare professionals who trust and prescribe them." The two companies said there would be no people transition from Sanofi India to Emcure under their distribution and promotion agreement.
Mint
7 days ago
- Business
- Mint
Cipla to enter into weight management segment in India, says MD Umang Vohra
Drugmaker Cipla's MD and global CEO Umang Vohra has announced that the company is planning to enter into the weight management segment in India. The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra said. In the CNS segment, the Mumbai-based company has successfully in-licensed Sanofi India's CNS product range, including Frisium, a leading brand in the anti-epileptic category, he added. He also said: "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease." Several domestic pharma companies are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. American drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in India. Denmark's Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. For fiscal year 2025, Cipla reported consolidated revenue of ₹ 27,548 crore. Its consolidated net profit increased to ₹ 5,272 crore. Umang Vohra further said the company is equally committed to addressing the global crisis of anti-microbial resistance (AMR). "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," he said. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," he added.
